Why UniQure Stock Is Soaring
Why UniQure Stock Is Soaring
UniQure N.V. (NASDAQ:QURE) shares are trading higher Tuesday after the company announced updated interim data from its ongoing U.S. and European Phase I/II clinical trials of AMT-130 for the treatment of Huntington's disease.
UniQure N.V. (纳斯达克：QURE)股票周二交易较高，因公司公布了AMt-130治疗亨廷顿病美国和欧洲的I / II期临床试验的最新中期数据。
The Details:
细节：
UniQure said a statistically significant, dose-dependent, slowing in disease progression measured by cUHDRS was observed through 24 months in patients receiving the high dose of AMT-130. The company also said it observed a statistically significant reduction of NfL in cerebrospinal fluid (CSF) in patients treated with AMT-130.
UniQure表示，接受高剂量AMt-130治疗的患者有统计学意义的剂量依赖性疾病进展减缓，通过cUHDRS衡量，疗程达24个月，该公司还表示，在接受AMt-130治疗的患者的脑脊液（CSF）中观察到了NfL的显着统计学减少。
"We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington's disease and lowering of NfL in the CSF at 24 months," stated Walid Abi-Saab, M.D., chief medical officer of UniQure.
“我们对这些新数据感到非常满意，这些数据表明了亨廷顿病的统计显着、剂量依赖性减缓和在24个月内降低CSF中的NfL，”UniQure的首席医学官Walid Abi-Saab万.D.说。
"We believe this is the first clinical trial of any investigational medicine for Huntington's disease to show evidence of a potential long-term clinical benefit and reduction of a key marker of neurodegeneration."
“我们认为这是任何亨廷顿病研究药物的第一项临床试验，显示出潜在长期临床益处和神经退行性关键标志物的降低。”
The company said it expects to hold a Type B, multi-disciplinary RMAT meeting with the U.S. Food and Drug Administration (FDA) to present the updated data and discuss potential expedited clinical development pathways and accelerated approval in the second half of 2024.
该公司表示，预计在2024年下半年与美国食品和药物管理局（FDA）举行b型多学科RMAt会议，以展示更新的数据并讨论潜在的加速临床发展路径和加速批准。
UniQure shares are moving on heavy trading volume following the company's announcement. According to data from Benzinga Pro, more than 27.7 million shares have already been traded in Tuesday's session, compared to the stock's 100-day average of less than 573,000 shares.
UniQure的股票公告后成交量激增。根据Benzinga Pro的数据，周二交易会话中已经交易了超过2770万股，而该股票的100日平均交易量不到57.3万股。
Is QURE A Good Stock To Buy?
QURE是否是一只好股票？
Wall Street analysts view UniQure on the whole as a Buy, given the history of coverage over the past three months. Uy Ear from Mizuho in UniQure is the most bearish, expecting a 14.29% fall in the stock in the coming year.
综合来看，华尔街分析师认为UniQure是买入的，这是基于过去三个月的覆盖历史。除了Mizuho的Uy Ear，预计该股票将下跌14.29%。
But looking at how the market as a whole thinks of the stock, you can reference historical price action for views on whether investors feel strongly about the stock one way or another. In the past 3 months, UniQure rose 11.69%, which indicates that opinion improved on the business and how attractive it is to own based on either its stock price, or underlying fundamentals, like revenue, which rose 59.34% over the past year.
但是，从市场整体对股票的看法来看，你可以参考历史价格走势，了解投资者对股票的看法是否有强烈的喜爱或厌恶。在过去的3个月中，UniQure上涨了11.69%，这表明基于股价或营业收入等基本面的投资者对公司和公司的吸引力的观点已得到改善。
A complete overview of how Wall Street views individual stocks is available here, while real time updates on the latest analyst actions will be delivered via Benzinga PRO. Try it for free.
可以在此处获得有关华尔街如何看待个股的完整概述，而最新分析师行动的实时更新将通过Benzinga PRO提供。立即免费试用。
QURE Price Action: According to Benzinga Pro, UniQure shares are up 59% at $6 at the time of publication Tuesday.
QURE价格行情: 根据Benzinga Pro的数据，UniQure股票上涨59%，报6美元，时间为周二的出版时间。
Read Also:
阅读更多：
- What's Going On With Nikola Stock?
- nikola股票的情况怎么样了？
Image: PublicDomainPictures from Pixabay
图片来自Pixabay的PublicDomainPictures。